FDA Warns Nupack Inc. Over Manufacturing Failures and Unauthorized Drug Claims

The U.S. Food and Drug Administration (FDA) issued a Warning Letter to Nupack Inc. in 2024 for significant violations of Good Manufacturing Practice (cGMP) standards and for marketing dietary supplements with unauthorized drug claims. The agency found that the company failed to establish quality control procedures, maintain production records, and investigate product quality issues—deficiencies that affect consumer confidence in supplements containing psyllium, maca, and other ingredients. Nupack was given fifteen business days to correct all violations, with the threat of product seizure and legal injunctions if compliance is not achieved.

What happened

An FDA inspection of Nupack Inc.'s manufacturing facility uncovered multiple deficiencies in current Good Manufacturing Practices. According to ConsumerLab's coverage of the Warning Letter, inspectors found that the company failed to establish and maintain written procedures ensuring dietary supplements were manufactured to established specifications. The facility also lacked adequate environmental monitoring systems and did not maintain records demonstrating that in-process and finished product testing was performed according to specifications.

Beyond manufacturing deficiencies, the FDA identified unauthorized marketing claims that characterized several Nupack products as drugs. These claims suggested the supplements could diagnose, cure, mitigate, treat, or prevent disease—language that crosses the regulatory line separating permissible structure-function claims (such as "supports digestive health") from illegal drug claims requiring FDA approval as a new drug application. Products containing psyllium and maca were among those cited for improper marketing language.

The Warning Letter demands that Nupack promptly correct all violations and provide a detailed corrective action plan within fifteen business days. The FDA warned that failure to comply may result in seizure of products and injunctive action.

What the source says

ConsumerLab's analysis of the FDA inspection findings details specific manufacturing deficiencies across multiple production areas. The facility failed to establish written procedures for quality control testing, lacked adequate documentation systems for in-process and finished product testing, and failed to retain records of investigations into customer complaints about product quality—a requirement under 21 CFR Part 111. These gaps create uncertainty about whether products met potency, purity, and safety standards.

The regulatory distinction between permissible health claims and illegal drug claims remains a frequent source of enforcement action in the supplement industry. The FDA emphasizes that dietary supplements must comply with cGMP regulations regardless of ingredient profile. Whether a supplement contains a well-established ingredient like psyllium—traditionally researched for fiber-based digestive support—or a less robustly studied ingredient like maca, the same manufacturing standards and labeling restrictions apply.

Beyond the headline

Nupack's Warning Letter reflects a broader pattern of FDA enforcement targeting supplement manufacturers with inadequate quality infrastructure. The dietary supplement industry operates under different regulatory rules than pharmaceuticals: supplements do not require pre-market FDA approval and are presumed safe. However, they must still comply with cGMP standards and are prohibited from making disease claims. Over the past five years, the FDA has intensified cGMP inspections and enforcement actions, issuing Warning Letters for similar violations—inadequate testing, poor documentation, environmental contamination risks—at dozens of facilities annually.

What makes Nupack's case notable is the combination of both manufacturing compliance failures and drug claim violations in a single enforcement action. This pattern suggests systemic control gaps rather than isolated missteps. The company now faces increased regulatory scrutiny, potential product recalls, and reputational damage that may affect consumer trust in its brands.

What this means for consumers

Consumers who purchased Nupack products should understand that the company failed to meet manufacturing standards designed to ensure product safety and potency. While this does not automatically indicate contamination or ineffectiveness, it means Nupack did not follow required procedures to verify these attributes.

If you own Nupack supplements—particularly those containing psyllium or maca—take these specific actions:

• Check for recalls: Visit the FDA's Enforcement Reports page or ConsumerLab's supplement database to confirm whether any Nupack products have been recalled or issued safety notices.
• Verify third-party testing: If you wish to continue using psyllium or maca, choose brands with third-party certification seals (USP, NSF, or ConsumerLab Verified) that document independent manufacturing oversight and ingredient verification.
• Scrutinize marketing claims: Be skeptical of any supplement marketed as treating, curing, or preventing disease. Legitimate dietary supplements use qualified language: "supports," "promotes," or "may help." If a product makes disease claims, ask your healthcare provider to verify them against peer-reviewed evidence.
• Know your ingredient's evidence base: Psyllium is a soluble fiber with substantial research support for digestive function. Maca, by contrast, has less robust clinical evidence. Before starting either ingredient, discuss the specific dose, timing, and potential interactions (such as with blood thinners or diabetes medications) with your healthcare provider.

What to watch next

Monitor whether Nupack issues a public corrective action plan within the fifteen-day deadline. The company's response will signal whether it intends to remediate violations, cease operations, or divest product lines.

Watch for formal recalls: if the FDA determines that products already distributed pose a safety risk due to contamination or mislabeling, a recall will be publicly announced on the FDA's Enforcement Reports page.

Broader FDA enforcement trends deserve attention as well. The agency has signaled intensified focus on cGMP compliance and drug claim violations across the supplement sector. Smaller manufacturers with limited quality infrastructure are particularly vulnerable to similar actions. Additionally, industry trade associations may respond with advocacy for regulatory clarity or compliance resources, especially regarding the supplement-versus-drug distinction.

For informed purchasing decisions, understand how supplements are regulated and stay current with FDA enforcement actions affecting products you use.